Literature DB >> 19660485

Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach.

Weihsueh A Chiu1, Miles S Okino, Marina V Evans.   

Abstract

We have developed a comprehensive, Bayesian, PBPK model-based analysis of the population toxicokinetics of trichloroethylene (TCE) and its metabolites in mice, rats, and humans, considering a wider range of physiological, chemical, in vitro, and in vivo data than any previously published analysis of TCE. The toxicokinetics of the "population average," its population variability, and their uncertainties are characterized in an approach that strives to be maximally transparent and objective. Estimates of experimental variability and uncertainty were also included in this analysis. The experimental database was expanded to include virtually all available in vivo toxicokinetic data, which permitted, in rats and humans, the specification of separate datasets for model calibration and evaluation. The total combination of these approaches and PBPK analysis provides substantial support for the model predictions. In addition, we feel confident that the approach employed also yields an accurate characterization of the uncertainty in metabolic pathways for which available data were sparse or relatively indirect, such as GSH conjugation and respiratory tract metabolism. Key conclusions from the model predictions include the following: (1) as expected, TCE is substantially metabolized, primarily by oxidation at doses below saturation; (2) GSH conjugation and subsequent bioactivation in humans appear to be 10- to 100-fold greater than previously estimated; and (3) mice had the greatest rate of respiratory tract oxidative metabolism as compared to rats and humans. In a situation such as TCE in which there is large database of studies coupled with complex toxicokinetics, the Bayesian approach provides a systematic method of simultaneously estimating model parameters and characterizing their uncertainty and variability. However, care needs to be taken in its implementation to ensure biological consistency, transparency, and objectivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660485     DOI: 10.1016/j.taap.2009.07.032

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  37 in total

1.  A physiologically based pharmacokinetic model for capreomycin.

Authors:  B Reisfeld; C P Metzler; M A Lyons; A N Mayeno; E J Brooks; M A Degroote
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

3.  Incorporation of the glutathione conjugation pathway in an updated physiologically-based pharmacokinetic model for perchloroethylene in mice.

Authors:  Chimeddulam Dalaijamts; Joseph A Cichocki; Yu-Syuan Luo; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicol Appl Pharmacol       Date:  2018-05-29       Impact factor: 4.219

4.  Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.

Authors:  Todd J Zurlinden; Garrett J Eppers; Brad Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Differential toxicity of water versus gavage exposure to trichloroethylene in rats.

Authors:  Angela R Stermer; David Klein; Shelby K Wilson; Chimeddulam Dalaijamts; Cathy Yue Bai; Susan J Hall; Samantha Madnick; Enrica Bianchi; Weihsueh A Chiu; Kim Boekelheide
Journal:  Environ Toxicol Pharmacol       Date:  2019-02-16       Impact factor: 4.860

6.  Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach.

Authors:  Todd J Zurlinden; Brad Reisfeld
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-01-31       Impact factor: 2.441

7.  Application of Markov chain Monte Carlo analysis to biomathematical modeling of respirable dust in US and UK coal miners.

Authors:  Lisa M Sweeney; Ann Parker; Lynne T Haber; C Lang Tran; Eileen D Kuempel
Journal:  Regul Toxicol Pharmacol       Date:  2013-02-27       Impact factor: 3.271

Review 8.  Trichloroethylene biotransformation and its role in mutagenicity, carcinogenicity and target organ toxicity.

Authors:  Lawrence H Lash; Weihsueh A Chiu; Kathryn Z Guyton; Ivan Rusyn
Journal:  Mutat Res Rev Mutat Res       Date:  2014 Oct-Dec       Impact factor: 5.657

9.  The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?

Authors:  Peter W Stacpoole
Journal:  Environ Health Perspect       Date:  2010-10-04       Impact factor: 9.031

10.  Characterizing the Effects of Race/Ethnicity on Acetaminophen Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Todd J Zurlinden; Brad Reisfeld
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.